Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lamin A/C as a Molecular Link Between Nuclear Organization, Chromatin Dynamics, and Tumor Progression.

Cells·2026
Same author

Microinvasive, off-pump, transventricular neochordae implantation in recurrent mitral valve regurgitation after open heart surgical repair.

The Journal of thoracic and cardiovascular surgery·2026
Same author

Reply to: Mifamurtide in Nonmetastatic High-Grade Osteosarcoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

VEGF Signaling Pathway Germline Polymorphisms as Prognostic Pharmacogenetic Biomarkers in Localized High-Grade Osteosarcoma Patients from the GEIS-33 Protocol.

Pharmaceuticals (Basel, Switzerland)·2025
Same author

Establishment and Characterization of OS-MET-R-092: A Novel Patient-Derived Cell Culture from an Osteosarcoma Bone Metastasis.

International journal of molecular sciences·2025
Same author

SMARCAL1 is a new osteosarcoma predisposition gene.

Journal of the National Cancer Institute·2025

Related Experiment Video

Updated: Jun 10, 2026

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
08:07

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

Emerging drugs for high-grade osteosarcoma.

Claudia Maria Hattinger1, Michela Pasello, Stefano Ferrari

  • 1Rizzoli Orthopaedic Institute, Pharmacogenomics and Pharmacogenetics Research Unit, Laboratory of Experimental Oncology, Via di Barbiano 1/10, 40136 Bologna, Italy.

Expert Opinion on Emerging Drugs
|August 10, 2010
PubMed
Summary
This summary is machine-generated.

Innovative treatments for high-grade osteosarcoma (OS) are emerging. This review highlights promising therapeutic markers and drugs in clinical trials for improved pediatric and adolescent OS care.

More Related Videos

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma
09:25

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Published on: October 14, 2016

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

Related Experiment Videos

Last Updated: Jun 10, 2026

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
08:07

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma
09:25

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Published on: October 14, 2016

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

Area of Science:

  • Oncology
  • Pediatric Oncology
  • Bone Cancers

Background:

  • Osteosarcoma (OS) is the most common primary malignant bone tumor in children and adolescents.
  • High-grade OS requires innovative treatment strategies.

Purpose of the Study:

  • To review promising therapeutic markers and drugs for high-grade OS.
  • To focus on agents evaluated in clinical trials for potential innovative treatments.

Main Methods:

  • Literature search covering the last 40 years of OS chemotherapy and targeted therapies.
  • Inclusion of drugs targeting clinically relevant markers in Phase I, II, or III trials.
  • Emphasis on novel targeted therapies for high-grade OS.

Main Results:

  • An updated overview of novel therapeutic approaches for high-grade OS.
  • Identification of agents currently in or planned for clinical studies.
  • Focus on treatments with potential clinical usefulness.

Conclusions:

  • New agents for innovative treatment strategies are anticipated within 5-10 years.
  • These agents may benefit selected subgroups of high-grade OS patients.
  • Continued research into targeted therapies is crucial for advancing OS treatment.